Actively Recruiting
Pediatric Liver Transplantation-Liver Fibrosis Evaluation by Using Fibrosis Panel
Led by RenJi Hospital · Updated on 2024-08-07
1200
Participants Needed
2
Research Sites
187 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Liver transplantation in children is highly successful with \>80% having 20 years survival. Most pediatric liver diseases are potentially curable with liver transplantation and it is important to establish whether children who have undergone successful transplantation can expect a normal life expectancy or whether there will be a gradual decline in liver function and eventual graft loss. The most common reasons in late graft loss in children are unexplained graft inflammation ("idiopathic" post-transplant hepatitis) and graft fibrosis. PRO-C3, a disintegrin and metalloproteinase with thrombospondin motifs-generated neo-epitope marker of type III collagen formation, has been proved to be a marker of fibrosis in patients with NAFLD. The aim of this study is to explore the role of Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA) in children received liver transplantation.
CONDITIONS
Official Title
Pediatric Liver Transplantation-Liver Fibrosis Evaluation by Using Fibrosis Panel
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participant must be between 8 weeks and 18 years of age.
- Participant is a recipient of a first liver allograft from cadaveric or living donors.
- Participant is a single-organ recipient (liver only).
- Participant's parent or guardian can understand the study and sign informed consent.
You will not qualify if you...
- Participants older than 18 years of age
- Pregnant or breastfeeding
- Active systemic infections
- Receiving any form of solid organ retransplantation
- Multiorgan transplantation
- Multi organ failure
- Congenital heart, lung, kidney, nervous system, or blood disease
- Refused to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China, 200127
Actively Recruiting
2
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China, 200127
Not Yet Recruiting
Research Team
Y
Yi ZHOU
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here